Search - tctmd.com

Displaying 1 - 20 of 24

Sort: Relevancy | Date

News Daily News

FDA Approves Triple Therapy Polypill for High Blood Pressure

Michael O'Riordan

June 10, 2025

News Daily News

FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades

Todd Neale

October 02, 2024

News Daily News

Little Pre- and Postmarket Testing for Most Recalled CV Devices

Michael O'Riordan

September 16, 2024

News Opinion CV Team Dispatch

June 2024 Dispatch for the CV Team

L.A. McKeown

June 01, 2024

News Daily News

FDA Grants Tirzepatide a New Indication for Obesity Management

L.A. McKeown

November 08, 2023

News Daily News

FDA Approves Paradise Renal Denervation System: What Comes Next?

Todd Neale

November 08, 2023

News Daily News

FDA Approves Colchicine for Decreasing CV Events

Caitlin E. Cox

June 20, 2023

News Daily News

Higher Annual TAVI Volumes Linked to Greater Use of Embolic Protection

L.A. McKeown

August 23, 2022

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

News Daily News

Papers Probe Temporal Link Between COVID-19 Vaccines and Myocarditis

Michael O'Riordan

June 17, 2021

News Daily News

Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles

Michael O'Riordan

May 12, 2021

News Features

Roughly 80% of ESC Guideline Writers Have Financial COIs

Michael O'Riordan

April 01, 2021

News Daily News

FDA Approves Shockwave Intravascular Lithotripsy for Calcified Coronaries

Shelley Wood

February 16, 2021

News Features

Funding the Future: How Industry Support for CV Trials Could Evolve

Michael O'Riordan

December 17, 2020

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

FDA Gives Rivaroxaban Another VTE-Related Indication

Todd Neale

October 14, 2019

News Daily News

FDA Expands TAVR Indication to Low-Risk Patients

Michael O'Riordan

August 16, 2019

News Daily News

Details in Print for DanGer Design as Impella AMICS RCT Expands From Denmark to Germany

Caitlin E. Cox

May 14, 2019

News Daily News

CV Devices in the Fast Lane: FDA’s Approval Often Rests on Early Evidence

Caitlin E. Cox

September 05, 2018

Advertisement

FDA Approves Triple Therapy Polypill for High Blood Pressure

FDA Approves First New PET Imaging Tracer for Cardiac Testing in Decades

Little Pre- and Postmarket Testing for Most Recalled CV Devices

June 2024 Dispatch for the CV Team

FDA Grants Tirzepatide a New Indication for Obesity Management

FDA Approves Paradise Renal Denervation System: What Comes Next?

FDA Approves Colchicine for Decreasing CV Events

Higher Annual TAVI Volumes Linked to Greater Use of Embolic Protection

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Papers Probe Temporal Link Between COVID-19 Vaccines and Myocarditis

Add-on CMS Payment Sweetens Shockwave Choice, but Cost Still Rankles

Roughly 80% of ESC Guideline Writers Have Financial COIs

FDA Approves Shockwave Intravascular Lithotripsy for Calcified Coronaries

Funding the Future: How Industry Support for CV Trials Could Evolve

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

FDA Gives Rivaroxaban Another VTE-Related Indication

FDA Expands TAVR Indication to Low-Risk Patients

Details in Print for DanGer Design as Impella AMICS RCT Expands From Denmark to Germany

CV Devices in the Fast Lane: FDA’s Approval Often Rests on Early Evidence

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content